Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04515238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04515238 · ClinicalTrials.gov record · last posted 2026-08-20

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Name: Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL — clinical trial record (NCT04515238)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CLL2-BZAG

StatusActive, Not Recruiting

PhasePhase 2

SponsorGerman CLL Study Group

Started2020-10-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

Protocol amendment history 2 changes detected by DataLookout

2026-08-21

Primary completion pushed: 2026-12 → 2027-02

2026-08-21

Completion pushed: 2026-12 → 2027-02

Trial Details

NCT Number	NCT04515238
Lead Sponsor	German CLL Study Group
Conditions	Chronic Lymphoid Leukemia
Enrollment	42 participants
Start Date	2020-10-01
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-20